Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Gout is a condition that is characterized by the formation of excess uric acid in body tissues that result in the formation of crystals of monosodium urate. Symptoms of gout include intense pain, swelling, and stiffness in the joints. Asia gout disease treatment market is expected to witness significant growth due to increasing number of pipeline products. For instance, Shanton Pharma Co., Ltd, a China-based biotech company, has its major drug candidate SAP-001 in pipeline. SAP-001 is developed as a new investigational Uric Acid Transporter 1 (URAT1) inhibitor for the chronic management of hyperuricemia and gout.

Asia Gout Disease Treatment Market– Impact of Coronavirus (Covid-19) Pandemic

The Covid – 19 pandemic is expected to drive growth of the Asia gout disease treatment market over the forecast period. Since December 2019, a novel coronavirus spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. The disease has spread to more than 100 countries across the globe and the World Health Organization declared it as a public health emergency. For instance, according to the World Health Organization Coronavirus Disease (COVID-19) Dashboard (WHO) report, the manifestation of the coronavirus disease (COVID-19) has resulted in more than 11 million infected individuals worldwide as of July 2020.

Furthermore, according to the CreakyJoints, May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID 19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one the sectors, which has been majorly impacted by the COVID 19 pandemic.

The Asia gout disease treatment market is estimated to be valued at US$ 643.55 Million in 2020 and is expected to exhibit a CAGR of 9.1% during the forecast period (2020-2027).

Figure 1: Asia Gout Disease Treatment Market Share (%) Analysis, By Drug Class, 2020

Asia Gout Disease Treatment  | Coherent Market Insights

Asia gout disease treatment market is expected to grow significantly in the near future, owing to presence of major market players

Market players are more focused on adoption of inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen their anti-gout drugs portfolio. For instance, in September 2019, Simcere Pharmaceutical Group and JW Pharmaceutical (both China-based companies) entered into a collaboration and exclusive license agreement for the development of anti-gout drug candidate URC-102 in China. Under this agreement, the responsibilities of clinical trial and registration will be taken by Simcere Pharmaceutical Group. The candidate, URC-102, is a selective inhibitor of uric acid transporter (URAT-1) and it is in Phase IIb clinical trial in patients with gout disease in South Korea.

Furthermore, big pharmaceutical companies such as Takeda Pharmaceutical and AstraZeneca adopted inorganic growth strategies. For instance, in April 2012, Takeda Pharmaceutical (Japan-based) acquired the URL Pharma Inc., a Philadelphia-based company, in order to expand its gout disease treatment portfolio with the acquisition of marketed gout therapy Colcrys (colchicine), developed by URL Pharma Inc.

Similarly, in December 2018, InventisBio announced that it had signed a collaboration agreement with Betta Pharma. Under this agreement, InventisBio will out-license D-0316's rights in China (including mainland China, Hong Kong, and Taiwan) to Betta Pharma and to co-develop this drug in China. Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.

request-sample

Asia Gout Disease Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 643.55 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.1% 2027 Value Projection: US$ 1,180.61 Mn
Geographies covered:
  • China, India, Japan, South Korea, Thailand, Indonesia, Singapore, Vietnam, Rest of Asian countries
Segments covered:
  • By Drug Class: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents.
  • By Route of Administration: Oral, Injectable.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem

Growth Drivers:
  • Adoption of Inorganic Strategies by Key Players
  • The Increasing Prevalence of Gout
  • The Rising Funding For Development of Novel Drugs
Restraints & Challenges:
  • Adverse effects and risks associated with drugs such as NSAIDS and urate-lowering agents

Asia Gout Disease Treatment Market– Restraints

The adverse effects and risks associated with drugs such as NSAIDS and urate-lowering agents is major factor restraining growth of this market. Most of the gout drugs are associated with some severe side effects, which may lead to decrease in demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In some cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal GI tract. Moreover, side effects such as intolerability and contraindication may limit the use of these drugs in the treatment of gout.

For instance, in February 2019, the U.S. Food and Drug Administration (FDA) announced to add a new boxed warning for febuxostat, as there is increased risk of death associated with Uloric (febuxostat) compared to another gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.

Figure 2: Asia Gout Disease Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Asia Gout Disease Treatment  | Coherent Market Insights

Asia Gout Disease Treatment Market– Competitive Landscape

Some of the key players operating in the Asia gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem.

Gout is a chronic disease characterized by the pain and inflammation in the joints. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of needle-like crystals in the joints resulting in inflammation and pain. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout in certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.

Market Dynamics

Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the Asia gout disease treatment market growth over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.

Moreover, increasing product approvals by regulatory authorities is expected to drive growth of the Asia gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets, to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Key features of the study:

  • This report provides in-depth analysis of the Asia gout disease treatment  market, market size and compound annual growth rate (CAGR (XX %)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the Asia gout disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The Asia gout disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for gout disease treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Asia Gout Disease Treatment  Market, By Drug Class:
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Colchicine
    • Urate-lowering Agents
  • Asia Gout Disease Treatment  Market, By Route of Administration:
    • Oral
    • Injectable
  • Asia Gout Disease Treatment  Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Asia Gout Disease Treatment  Market, By Country:
    • China
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • India
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Japan
      • By Type:
        • Linear Array Probe
        • Annular Array Probe
        • Circular Array Probe
        • Matrix Array Probe
      • End User:
        • Diagnostic Clinics
        • Hospitals
        • Others
    • South Korea
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Thailand
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
    • Indonesia
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Singapore
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Vietnam
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Rest of Asian Countries
      • By Drug Class:
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Corticosteroids
        • Colchicine
        • Urate-lowering Agents
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • AstraZeneca Plc
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Takeda Pharmaceutical Company Limited
    • Teijin Pharma Limited
    • Hikma Pharmaceuticals Plc.
    • CymaBay Therapeutics, Inc.
    • Zyla Life Sciences
    • Horizon Therapeutics plc
    • JW Pharmaceutical CORPORATION
    • LG Chem

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of  Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Country
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • Key Developments
    • PEST Analysis
    • Epidemiology
  4. Covid – 19 Impact Analysis
    • Pre-COVID 19 Market Situation
    • Post Covid - 19 Market Scenario
    • Overall Impact on the Healthcare Industry
  5. Asia Gout Disease Treatment Market, By Drug Class, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Colchicine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Urate-lowering Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Asia Gout Disease Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Asia Gout Disease Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Asia Gout Disease Treatment , By Country, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • China
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • India
      •  Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Japan
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • South Korea
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Thailand
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Indonesia
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Singapore
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Vietnam
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Rest of Asian Countries
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  9. Competitive Landscape
    • Company Profiles
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teijin Pharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hikma Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CymaBay Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zyla Life Sciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • JW Pharmaceutical CORPORATION
        •  Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • LG Chem
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 41 market data tables and 33 figures on “Asia Gout Disease Treatment Market” - Forecast to 2027”

Frequently Asked Questions

The Asia gout disease treatment market is expected to register a CAGR of 9.1% during the forecast period (2020-2027).
The value of Asia gout disease treatment market is estimated to be US$ 643.5 Mn in 2020.
The prominent players in the Asia gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem.
The Asia gout disease treatment market is expected to be valued at US$ 1,180.6 Mn in 2027.
The adoption of inorganic strategies and rising funding for development of novel drugs is expected to drive growth for this market.
China is a major region in the Asia gout disease treatment market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner